79335-75-4
Chemical Structure
FK-565
- CAS No.: 79335-75-4
- Formula:C22H38N4O9
- Molecular Weight:502.56
IUPAC Name: (2R,6S)-2-amino-6-((R)-4-carboxy-4-heptanamidobutanamido)-7-(((R)-1-carboxyethyl)amino)-7-oxoheptanoic acid
InChIKey: ZRWBSKCFKHSDHD-LVQVYYBASA-N
SMILES: CCCCCCC(N[C@@H](C(O)=O)CCC(N[C@@H](CCC[C@@H](N)C(O)=O)C(N[C@H](C)C(O)=O)=O)=O)=O
Biological Activity: FK-565 is a synthetic immunomodulatory peptide with a nucleotide oligomerization domain-1 (NOD1) ligand. FK-565 can activate macrophages, NK cells, and peritoneal exudative cells, enhancing the innate immune response. FK-565 has antiviral activity against a variety of viruses in vivo, and its effect is achieved through immunomodulation rather than direct viral inhibition. FK-565 can induce mouse models of arteritis and coronary arteritis (Kawasaki disease-like disease) through a NOD1-mediated mechanism. FK-565 can be used for research on viral infections and inflammatory vascular diseases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FK-565 | 99.88% | FK-565 is a synthetic immunomodulatory peptide with a nucleotide oligomerization domain-1 (NOD1) ligand. FK-565 can activate macrophages, NK cells, and peritoneal exudative cells, enhancing the innate immune response. FK-565 has antiviral activity against a variety of viruses in vivo, and its effect is achieved through immunomodulation rather than direct viral inhibition. FK-565 can induce mouse models of arteritis and coronary arteritis (Kawasaki disease-like disease) through a NOD1-mediated mechanism. FK-565 can be used for research on viral infections and inflammatory vascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yokota Y, et al. Inhibitory effect of FK-565 alone and in combination with zidovudine on retroviral infection by Friend leukemia virus in mice. J Antibiot (Tokyo). 1988 Oct;41(10):1479-87.
- [2]. Sato Y, et al. Treatment of coxsackievirus B3 myocarditis by immunoactive peptide in an animal model. Clin Immunol Immunopathol. 1992 Oct;65(1):65-9.
- [3]. Sato Y, et al. Effect of immunostimulant therapy on acute viral myocarditis in an animal model. Am Heart J. 1992 Aug;124(2):428-34.
- [4]. Ohashi R, et al. Characterization of a murine model with arteritis induced by Nod1 ligand, FK565: A comparative study with a CAWS-induced model. Mod Rheumatol. 2017 Nov;27(6):1024-1030. [Content Brief]
- [5]. Murata K, et al. Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease. Clin Exp Immunol. 2017 Oct;190(1):54-67.
